The corporate-backed mobile wallet provider has secured a blend of debt, equity and warrant financing totalling $29.7m from an investor called MK SPV IX.
Unilever Ventures returned to back a round led by Temasek that expanded the health and wellness services platform's overall financing to approximately $390m.
Strategic partner Lyell Immunopharma led a $45m round for Eureka Therapeutics, which will use the money to advance a pipeline that includes a treatment for liver cancer.
Unnamed investors have added $1.2bn to a round already featuring AIA, Mitsubishi, Visa, SCB, Astra International,
Tencent, JD.com and Google that reportedly now totals near $3bn.
The pharmaceutical firm was among the investors in a series G round that valued precision medicine technology provider Tempus at $5bn.
Alphabet-backed meat substitute provider Impossible said it plans to use the series F funding to shore up against expected disruption by the coronavirus pandemic.